H.C. Wainwright lowered the firm’s price target on AngioDynamics to $14 from $18 and keeps a Buy rating on the shares after the company completed the sale of its PICC and Midline product portfolios for up to $45M in cash. The firm says that in order to improve gross margin and advance towards profitability, AngioDynamics has initiated a restructuring towards an outsourced model of manufacturing.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ANGO:
- AngioDynamics Announces Key Leadership and Board Changes
- FDA clears AngioDynamics Auryon XL Catheter to treat Peripheral Arterial Disease
- AngioDynamics’ Long-Time Director Meteny Retires
- AngioDynamics price target lowered to $17 from $19 at Canaccord
- AngioDynamics price target lowered to $18 from $20 at H.C. Wainwright
